Northstrive Biosciences has received preliminary feedback from the FDA on its nonclinical studies and clinical plans for its product, EL-22, intended for use alongside GLP-1 receptor agonists in ...
Shattuck Labs, Inc. has announced progress in its SL-325 program, with an Investigational New Drug (IND) filing expected in the third quarter of 2025. The company reported a cash balance of ...
INDIANAPOLIS—In an election cycle expected to be partially shaped by Indiana’s redistricting debate, dozens of Hoosiers announced their intentions to run for office during the first day of the ...
FibroBiologics (FBLG) announced the filing of a Phase 1/2 Investigational New Drug application with the U.S. Food and Drug Administration seeking regulatory clearance to initiate clinical trials of ...
– Positive preclinical results of the small-diameter ATEV were recently presented at The American Heart Association’s Scientific Sessions 2024 meeting – DURHAM, N.C., Jan. 21, 2025 (GLOBE NEWSWIRE) -- ...
HOUSTON, Dec. 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the ...
Abpro Holdings Inc. and Celltrion Inc. have announced the submission of an IND application to the FDA for ABP-102 (CT-P72), a HER2 x CD3 T-cell engager. Pending clearance, a phase I trial in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results